安罗替尼三线治疗晚期卵巢癌的疗效

Efficacy of anlotinib in the third-line treatment of advanced ovarian cancer

目的以安罗替尼作为晚期卵巢癌三线治疗药物,观察其在临床中的治疗效果及毒副反应,评价该治疗方式的临床价值。方法选择2020年5月1日—2022年4月30日就诊于武威市人民医院的晚期卵巢癌患者60例。采用随机数表法将患者分为对照组(30例)和治疗组(30例),治疗组使用安罗替尼三线治疗,对照组仅给予最佳支持治疗,比较2组患者的客观缓解率(ORR)、疾病控制率(DCR)、生活质量(KPS评分)及无进展生存期(PFS),并观察使用安罗替尼治疗的毒副反应,评价使用安罗替尼的有效性和安全性。结果治疗组患者ORR与DCR分别为26.7%(8/30)、86.7%(26/30);对照组患者ORR与DCR分别为0、23.3%(7/30),2组患者ORR、DCR比较差异均有统计学意义(均P<0.05)。治疗后,治疗组患者KPS评分为(82.17±9.56)分,显著高于对照组的(75.18±9.15)分,差异有统计学意义(t=2.893,P=0.005)。治疗组部分患者用药期间出现恶心呕吐、胃肠胀气、腹泻、疲乏、高血压及食欲减退等毒副反应,但均可耐受,未影响治疗。结论安罗替尼三线治疗晚期卵巢癌,近期临床疗效较好,安全性较高。

Objective To observe the clinical efficacy and toxicity of anlotinib as a third-line treatment for advanced ovarian cancer,and to evaluate the clinical value of this treatment.Methods A total of 60 patients with advanced ovarian cancer who were treated in Wuwei People's Hospital from May 1,2020 to April 30,2022 were selected.The patients were divided into control group(n=30)and treatment group(n=30)by random number table method.The treatment group was treated with anlotinib as third-line treatment,and the control group was only given best supportive treatment.The objective response rate(ORR),disease control rate(DCR),quality of life(KPS score)and progression-free survival(PFS)of the two groups were compared.The side effects of anlotinib treatment were observed to evaluate the efficacy and safety of anlotinib.Results The ORR and DCR of the treatment group were 26.7%(8/30)and 86.7%(26/30),respectively.The ORR and DCR of the control group were 0 and 23.3%(7/30),respectively.There were significant differences in ORR and DCR between the two groups(both P<0.05).After treatment,the KPS score of the treatment group was(82.17±9.56)points,which was significantly higher than(75.18±9.15)points of the control group,and the difference was statistically significant(t=2.893,P=0.005).Some patients in the treatment group had nausea and vomiting,flatulence,diarrhea,fatigue,hypertension and loss of appetite during the treatment,but they could be tolerated and did not affect the treatment.Conclusion Anlotinib as a third-line treatment for advanced ovarian cancer has good short-term clinical efficacy and high safety.